Bluejay Diagnostics, Inc. is a healthcare company focused on the development and commercialization of innovative diagnostic solutions that improve patient care and streamline clinical decision-making
The company leverages advanced technologies to create rapid, cost-effective testing methods for various medical conditions, aiming to enhance diagnostic accuracy and efficiency in both laboratory and point-of-care settings. By prioritizing patient needs and leveraging cutting-edge research, Bluejay is positioned to make significant advancements in the realm of medical diagnostics, ultimately contributing to better health outcomes.
Bitech Technologies Corp. (OTCQB: BTTC)an independent power provider developing utility-scale battery energy storage initiatives and innovative renewable solutions has appointed Montgomery Bannerman as an Independent Director, adding over 35 years of expertise in energy to its Board. Bannerman, a seasoned leader with roles as CEO ArcStar Energy, and CEO of Verso Technologies (NYSE: VRS), brings valuable experience in renewable energy infrastructure. His background in developing large-scale renewable energy networks, including microgrid projects with MicroGrid Networks, aligns with Bitech’s strategy to expand Distributed Energy Resources Interconnections (DERI) and Distributed Photovoltaics (DPV) in key regions throughout the US.
Bluejay (NASDAQ: BJDX), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, recently announced the closing of a firm commitment underwritten public offering. Expected gross proceeds to the company were approximately $8.75 million. The base offering consisted of 5,368,098 common units or prefunded units, each unit consisting of one share of the company’s common stock or one pre-funded warrant to purchase one share of common Stock, two Class C warrants each to purchase one share of common stock and one Class D warrant to purchase such number of shares of common stock as determined in the Class D warrant. In addition, the company granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or common warrants, representing up to 15% of the number of securities sold in the offering, solely to cover over-allotments, if any.
Bluejay (NASDAQ: BJDX) is a medical diagnostics company that offers the Symphony technology platform, Symphony Cartridge and tests and testing devices for the diagnosis of allergic conjunctivitis and monitoring of disease progression in critical care settings. Aegis Capital Corp. announced that it acted as exclusive placement agent on a ~$2.2 million private placement for Bluejay Diagnostics.
